In an animal model of obesity and diabetes chronic oxytocin treatment led to a reduction in visceral adipose tissue inflammation and plasma markers of systemic inflammation, which may play a role in disease progression. Here, OXT is linked to obesity due to melanocortin 4 receptor deficiency.